PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab
…, HM Verheul, CW Menke… - Journal of Nuclear …, 2015 - Soc Nuclear Med
PET/CT imaging allows for image-based estimates of organ and red marrow (RM) residence
times. The aim of this study was to derive PET/CT-based radiation dosimetry for 89 Zr-…
times. The aim of this study was to derive PET/CT-based radiation dosimetry for 89 Zr-…
Tumor uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma during ipilimumab treatment
Introduction Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment
of metastatic melanoma and significantly improves overall survival. Because of the high …
of metastatic melanoma and significantly improves overall survival. Because of the high …
ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment
…, CW Menke-van der Houven van Oordt… - Clinical Cancer …, 2016 - AACR
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers,
making it a potential drug target. We performed an 89 Zr-PET imaging study with …
making it a potential drug target. We performed an 89 Zr-PET imaging study with …
Validation of simplified dosimetry approaches in 89 Zr‐PET/CT: The use of manual versus semi‐automatic delineation methods to estimate organ absorbed doses
…, FHP van Velden, MC Huisman, CW Menke… - Medical …, 2014 - Wiley Online Library
Purpose: Increasing interest in immuno‐positron emission tomography (PET) studies
requires development of dosimetry methods which will provide accurate estimations of organ …
requires development of dosimetry methods which will provide accurate estimations of organ …
[HTML][HTML] Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis
…, AJ de Langen, CW Menke-Van der Houven… - Oncotarget, 2018 - ncbi.nlm.nih.gov
With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasive
genotyping in clinical practice. Radiogenomics is a rapidly evolving field of …
genotyping in clinical practice. Radiogenomics is a rapidly evolving field of …
[PDF][PDF] Neutrophils kill antibody-opsonized cancer cells by trogoptosis
…, T Matozaki, E Suzuki, CW Menke-van der Houven… - Cell reports, 2018 - cell.com
Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through
antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-…
antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-…
Biodistribution of 18F-FES in patients with metastatic ER+ breast cancer undergoing treatment with rintodestrant (G1T48), a novel selective ER degrader
…, R Boellaard, CW Menke-Van der Houven - Journal of Nuclear …, 2022 - Soc Nuclear Med
16α- 18 F-fluoro-17β-estradiol ( 18 F-FES) is a PET tracer characterizing the expression of the
estrogen receptor (ER). Because therapy can interfere with the kinetics and biodistribution …
estrogen receptor (ER). Because therapy can interfere with the kinetics and biodistribution …
Decalcification of breast cancer bone metastases with EDTA does not affect ER, PR, and HER2 results
…, J Overbosch, CW Menke-van der Houven… - The American Journal …, 2019 - journals.lww.com
In metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. …
(PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. …
[HTML][HTML] 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
CW Menke-van der Houven, EC Gootjes… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are
used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients …
used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients …
[HTML][HTML] Diagnostic Performance of [18F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
…, R Boellaard, CW Menke-van der Houven van Oordt - Diagnostics, 2021 - mdpi.com
Positron emission tomography using [ 18 F]fluorodeoxyglucose (FDG PET) potentially
underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast …
underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast …